Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On
February 1, 2022, Intec Pharma Ltd. (“Intec”), a wholly owned subsidiary of Indaptus Therapeutics, Inc. (the
“Company”) entered into an employment agreement (the “Employment Agreement”) with Nir Sassi, the
Company’s Chief Financial Officer. Mr. Sassi previously served as a consultant to the Company prior to 2022. The Employment
Agreement provides for an annual base salary of $345,000, subject to review for an upward adjustment on at least an annual basis.
Mr. Sassi is eligible to participate in an annual executive bonus plan, pursuant to which he may earn an annual target bonus of up
to 40% of his base salary, based on the achievement of certain individual and company-wide objectives, which shall be established by
the Company’s board of directors (the “Board”) on an annual basis. In connection with his employment, subject to
the approval of the Board, Mr. Sassi will also be eligible to receive from time to time stock options or other equity awards in
amounts, if any, to be approved by the Board. In addition, Mr. Sassi shall be entitled to such other benefits as in effect for
executive employees from time to time. In connection with the entry into of the Employment Agreement, the Company terminated
Mr. Sassi’s consulting services agreement and separately agreed to pay a $195,728 termination payment to Mr. Sassi.
Under
the Employment Agreement, both Intec and Mr. Sassi have the right to terminate the agreement and his employment at any time, subject
to certain notice requirements described therein. The Employment Agreement may terminate upon the earliest to occur of (i) termination
by the Company without cause, subject to a one month written notice, (ii) immediate termination by Intec for cause (in some cases subject
to a reasonable cure period, if susceptible to cure), (iii) immediate termination by Mr. Sassi for good reason (subject to Mr. Sassi
providing written notice within 90 days after he becomes aware of the event or circumstance which he believes constitutes good reason,
Intec’s failure to cure within 30 days after such notice, and Mr. Sassi’s resignation within 30 days of the expiration of
such cure period), (iv) termination by Mr. Sassi without good reason, subject to a one month written notice, (v) Mr. Sassi’s death,
or (vi) termination by reason of Mr. Sassi’s disability.
In
the event that Mr. Sassi’s employment terminates by reason of his death or disability, and Mr. Sassi is entitled to receive a bonus
for the year of termination based on the achievement of pre-determined performance goals (and ignoring any continuation of employment
requirements), Mr. Sassi (or his representatives) shall be entitled to receive such bonus on the same basis as the other participants
in the bonus plan, except that the bonus amount shall be prorated based on the percentage of days Mr. Sassi was employed relative to
the total number of days in the bonus earning period.
Upon
termination of Mr. Sassi’s employment by Intec without cause or Mr. Sassi’s resignation for good reason, Mr. Sassi will be
entitled to a severance benefit equal to twelve months of his base salary as in effect prior to the termination date, payable in accordance
with the Company’s payroll practices. In addition, if Mr. Sassi is entitled to receive a bonus for the year of termination based
on the achievement of pre-determined performance goals (and ignoring any continuation of employment requirements), Mr. Sassi (or his
representatives) shall be entitled to receive such bonus on the same basis as the other participants in the bonus plan, except that the
bonus amount shall be prorated based on the percentage of days Mr. Sassi was employed relative to the total number of days in the bonus
earning period.
If
Mr. Sassi’s employment is terminated by Intec without cause or by Mr. Sassi for good reason during the one year period immediately
following a change in control or six months before a change in control, then Mr. Sassi will be entitled to receive, (i) twelve months
of his base salary as in effect prior to the termination date plus his annual target bonus, payable in accordance with the Company’s
payroll practices, (ii) the current year bonus at the target level at a prorated basis, which shall be paid within 30 days of termination,
and (iii) full accelerated vesting of all of outstanding equity incentive awards upon the later of the change in control or Mr. Sassi’s
termination of employment.
The
Employment Agreement also includes provisions regarding confidentiality, the assignment of intellectual property to Intec and reimbursement
of expenses.
The
foregoing summary of the Employment Agreement is not complete and is qualified in its entirety by reference to the full text of such
agreement, a copy of which will be filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December
31, 2021, and is incorporated herein by reference.